James Quigley

Stock Analyst at Morgan Stanley

(0)
# 4873
Out of 5,370 analysts
29
Total ratings
66.67%
Success rate
-21.51%
Average return
8 Stocks
Name Action PT Current % Upside Ratings Updated
KYMR Kymera Therapeutics
Upgrades: Overweight
49 79
46.85 68.62% 6 Jun 3, 2025
SNY Sanofi
Initiates Coverage On: Neutral
65
49.38 31.63% 1 Mar 21, 2025
NVS Novartis
Downgrades: Neutral
119 121
118.11 2.45% 1 Sep 5, 2024
MOR MorphoSys
Downgrades: Equal-Weight
n/a
n/a n/a 6 Jan 19, 2024
GRFS Grifols
Maintains: Neutral
10 11
9.09 15.51% 1 Dec 5, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
42 40
28.82 38.79% 10 Aug 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
12 16
4.12 288.35% 3 Jun 23, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
25
n/a n/a 1 Nov 20, 2017